HTG Molecular Diagnostics - HTGM Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HTGM shares.
View HTGM analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 1-year price objectives for HTG Molecular Diagnostics' shares. Their HTGM share price forecasts range from $2.00 to $3.50. On average, they predict the company's stock price to reach $2.83 in the next twelve months. This suggests that the stock has a possible downside of 23.2%.
View analysts price targets for HTGM or view top-rated stocks among Wall Street analysts.

HTG Molecular Diagnostics saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 48,300 shares, a decline of 55.8% from the February 28th total of 109,300 shares. Based on an average daily volume of 1,290,000 shares, the short-interest ratio is presently 0.0 days. Approximately 6.6% of the shares of the stock are short sold.
View HTG Molecular Diagnostics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our HTGM earnings forecast.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) announced its earnings results on Wednesday, November, 10th. The medical research company reported ($0.60) earnings per share for the quarter, hitting the consensus estimate of ($0.60). The medical research company had revenue of $2.52 million for the quarter, compared to the consensus estimate of $2.90 million. HTG Molecular Diagnostics had a negative trailing twelve-month return on equity of 310.67% and a negative net margin of 324.66%. During the same period in the previous year, the company posted ($1.05) earnings per share.

HTG Molecular Diagnostics issued an update on its FY 2022 earnings guidance on Friday, January, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $6.40 million-$6.40 million, compared to the consensus revenue estimate of $5.70 million.

11 employees have rated HTG Molecular Diagnostics Chief Executive Officer Tim (TJ) Johnson on Glassdoor.com. Tim (TJ) Johnson has an approval rating of 47% among the company's employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

(HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

HTG Molecular Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.

One share of HTGM stock can currently be purchased for approximately $3.69.

HTG Molecular Diagnostics (NASDAQ:HTGM) has a market capitalization of $3.39 million and generates $8.91 million in revenue each year. The medical research company earns $-17,150,000.00 in net income (profit) each year or ($29.4118) on an earnings per share basis.

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The official website for the company is www.htgmolecular.com. The medical research company can be reached via phone at (520) 547-2827, via email at arr@lifesciadvisors.com, or via fax at 520-547-2837.